Immune-Mediated Hemolytic Anemia in Dogs and Cats: Symptoms, Treatment and Survival

Immune-Mediated Hemolytic Anemia in Dogs and Cats: Symptoms, Treatment and Survival

By Dr Duncan Houston

Immune-mediated hemolytic anemia, usually shortened to IMHA, is one of the most serious blood disorders seen in veterinary medicine.

A dog or cat may initially appear tired, refuse food or breathe slightly faster than normal. Within hours, the red blood cell count can fall further, oxygen delivery can become inadequate and the patient may collapse.

IMHA is an emergency, but it is not automatically hopeless. Blood transfusions, immunosuppressive treatment, prevention of blood clots and careful monitoring can save lives. The first days and weeks are usually the most dangerous. Animals that respond during this early period may go on to have a good long-term quality of life.

Quick Answer

IMHA is a potentially life-threatening condition in which the immune system targets red blood cells and causes them to be destroyed faster than the body can replace them.

Pale or yellow gums, marked weakness, rapid breathing, dark urine, collapse or an inability to stand require immediate veterinary care. Diagnosis requires evidence of anemia, immune-mediated red blood cell destruction and hemolysis. A positive Coombs test alone is not enough.

Treatment commonly involves hospitalisation, red blood cell transfusion when oxygen delivery is compromised, immunosuppressive medication, treatment of any associated disease and, in most dogs, medication to reduce the risk of dangerous blood clots.

What Is Immune-Mediated Hemolytic Anemia?

Red blood cells carry oxygen from the lungs to tissues throughout the body.

In IMHA, antibodies bind to the surface of red blood cells. The affected cells may then be:

• Removed by macrophages in the spleen and liver

• Damaged as they pass through the circulation

• Destroyed inside blood vessels through activation of the complement system

• Broken down faster than the bone marrow can replace them

Removal of red blood cells by the spleen and liver is called extravascular hemolysis. Destruction within blood vessels is called intravascular hemolysis. Some patients have evidence of both processes.

The consequences can include:

• Severe anemia

• Reduced oxygen delivery

• Jaundice

• Dark urine

• Inflammation

• Blood clot formation

• Organ dysfunction

• Collapse and death

The real danger is not simply that the red blood cell count is low. It is that the body may no longer be able to deliver enough oxygen while simultaneously developing a strong inflammatory and prothrombotic response.

Primary, Secondary, Associative and Non-Associative IMHA

IMHA has traditionally been divided into:

• Primary or idiopathic IMHA, where no underlying cause is found

• Secondary IMHA, where another disease, infection, drug, toxin or exposure appears to have triggered the immune response

The ACVIM consensus proposed using the terms non-associative and associative instead.

Non-associative IMHA means that no relevant concurrent condition was identified. Associative IMHA means that a concurrent disease or exposure was found, but it does not automatically prove that the condition caused the IMHA. This terminology better reflects how difficult it can be to establish true causation.

What Are the Symptoms of IMHA?

Signs may develop over several days or appear very suddenly.

Common symptoms include:

• Marked lethargy

• Weakness

• Reduced interest in walking or playing

• Collapse

• Pale, white or cream-coloured gums

• Yellow gums, eyes or skin

• Rapid breathing

• Increased breathing effort

• A fast heart rate

• Reduced appetite

• Vomiting

• Fever

• Dark red, brown or orange urine

• Abdominal discomfort

• Exercise intolerance

• Sudden deterioration after appearing mildly unwell

Some animals initially show vague signs such as sleeping more, walking slowly or refusing one meal. Owners may not recognise severe anemia until the gums become very pale or the animal collapses.

What does dark urine mean?

Dark urine in a patient with IMHA may contain:

• Free hemoglobin released from destroyed red blood cells

• Bilirubin produced during red blood cell breakdown

• Concentrated urine caused by dehydration

• Blood from the urinary tract

Dark urine supports concern for hemolysis, but it does not diagnose IMHA by itself. Urinary infection, bleeding, muscle damage and other disorders can produce similar colour changes.

Do all animals with IMHA become jaundiced?

No.

Jaundice develops when bilirubin accumulates faster than the liver can process and remove it. Some patients have severe anemia before yellow discolouration becomes obvious.

Do not wait for jaundice before seeking care. A profoundly anemic animal may have pale gums without any visible yellow colour.

How Worried Should You Be?

Any suspected case of IMHA deserves urgent veterinary assessment. There is no reliable home method for determining how quickly the red blood cell count is falling.

Risk level	What you may notice	What to do
Possible IMHA	Reduced energy, pale gums, poor appetite or unexplained weakness	Arrange same-day veterinary assessment
Severe	Very pale or yellow gums, dark urine, rapid breathing, pronounced weakness or difficulty walking	Go to an emergency veterinary hospital
Critical	Collapse, inability to stand, altered awareness, open-mouth breathing, severe breathing effort or white gums	Immediate emergency treatment is required
Possible relapse	A previously diagnosed patient becomes pale, weak, jaundiced, inappetent or unusually breathless	Contact the treating veterinarian immediately and arrange urgent rechecking

A pet does not need to have every classic symptom. Pale gums combined with weakness or rapid breathing are enough to justify emergency assessment.

How Do Veterinarians Diagnose IMHA?

There is no single test that confirms every case.

A firm diagnosis is built from three types of evidence:

1. The patient is anemic.

2. There is evidence that the immune system is targeting red blood cells.

3. There is evidence that red blood cells are being destroyed.

The ACVIM diagnostic framework recommends combining these findings rather than relying on one blood smear change or one positive antibody test.

Confirming Anemia

The first step is measuring the proportion and concentration of red blood cells.

Tests may include:

• Packed cell volume, or PCV

• Hematocrit

• Hemoglobin concentration

• Complete blood count

• Reticulocyte count

• Blood smear examination

A spun PCV is often particularly useful because severe red cell agglutination can interfere with automated hematology analyser calculations.

Does IMHA always cause regenerative anemia?

No.

Regenerative anemia means that the bone marrow is releasing increased numbers of immature red blood cells, called reticulocytes, to replace those being lost.

Approximately 30% of dogs with IMHA do not show an appropriate regenerative response at presentation. In many cases, the disease developed too recently for the bone marrow response to appear. Lack of regeneration during the first examination therefore does not exclude IMHA.

Persistent non-regenerative anemia raises additional concerns, including:

• Precursor-targeted immune-mediated anemia

• Bone marrow disease

• Severe inflammatory disease

• Kidney disease

• Cancer

• Drug effects

• Nutritional or metabolic abnormalities

Bone marrow testing may be recommended when regeneration does not develop as expected.

Looking for Immune-Mediated Red Blood Cell Destruction

Spherocytes

Spherocytes are small, dense red blood cells that have lost part of their surface membrane.

A significant number of spherocytes supports IMHA in dogs, although other causes of spherocyte-like cells must still be considered.

Spherocytes are not a reliable diagnostic criterion in cats because feline red blood cells do not consistently have the central pale area needed to recognise this change confidently.

Autoagglutination

Autoagglutination occurs when antibodies cause red blood cells to stick together in visible clusters.

A saline agglutination test helps distinguish true immune-mediated clumping from rouleaux, where red cells stack because of protein changes or other conditions.

Persistent agglutination after appropriate saline dilution or washing provides strong evidence of immune-mediated red cell destruction. A mildly grainy blood sample without proper confirmation should not automatically be called autoagglutination.

Direct antiglobulin test

The direct antiglobulin test, commonly called the Coombs test, looks for antibodies or complement attached to red blood cells.

A positive result can support the diagnosis, but the test is neither perfectly sensitive nor perfectly specific.

A patient can have IMHA with a negative Coombs result. A positive result can also occur in other diseases. The result must be interpreted alongside anemia, evidence of hemolysis, the blood smear and the clinical presentation.

Looking for Evidence of Hemolysis

Evidence that red blood cells are being destroyed may include:

• Increased bilirubin

• Jaundice

• Bilirubin in the urine

• Hemoglobin in the plasma

• Hemoglobin in the urine

• Ghost cells on a fresh blood smear

• Rapid unexplained reduction in PCV or hematocrit

• Marked reticulocytosis after sufficient time has passed

The veterinarian must also consider sample damage. Difficult blood collection or improper sample handling can rupture red blood cells outside the body and create a misleading appearance of hemolysis.

What Other Tests May Be Needed?

The initial investigation commonly includes:

• Complete blood count

• Manual PCV

• Reticulocyte count

• Blood smear review

• Serum biochemistry

• Bilirubin measurement

• Urinalysis

• Saline agglutination testing

• Coombs testing when indicated

• Blood pressure

• Coagulation testing

• Blood typing and crossmatching if transfusion is possible

Additional investigations may include:

• Vector-borne disease testing

• Hemotropic Mycoplasma PCR in cats

• FeLV and FIV testing

• Thoracic radiographs

• Abdominal ultrasound

• Specific toxin testing

• Infectious disease PCR or serology

• Bone marrow sampling

• CT imaging in selected patients

Lactate may help assess the severity of impaired oxygen delivery and response to stabilisation, but it is not an IMHA diagnostic test.

What Else Can Look Like IMHA?

Not every patient with anemia, jaundice or dark urine has IMHA.

Important differential diagnoses include:

Internal or external blood loss

Bleeding into the abdomen, chest, gastrointestinal tract or another location can produce severe anemia and collapse.

Potential causes include trauma, clotting disorders, ulcers and ruptured tumours.

Oxidative damage

Substances such as zinc, onions, garlic and certain medications can damage red blood cells directly.

Acetaminophen is particularly dangerous to cats. Oxidative injury may produce Heinz bodies or other characteristic blood smear changes.

Infectious hemolysis

Babesia species can destroy red blood cells in dogs and cats in relevant geographical regions.

Mycoplasma haemofelis is an important cause of hemolytic anemia in cats.

Microangiopathic hemolysis

Red blood cells may be damaged as they pass through abnormal blood vessels or fibrin strands.

This can occur with:

• Disseminated intravascular coagulation

• Vascular tumours

• Severe vasculitis

• Heart or vascular abnormalities

• Hemolytic uraemic syndrome

Transfusion reactions

A mismatched or delayed transfusion reaction can cause red blood cell destruction.

Bone marrow disease

Bone marrow disorders usually impair production rather than destroy circulating cells, but the clinical presentation can overlap, particularly when the anemia is non-regenerative.

The mistake is seeing one spherocyte, one positive Coombs result or one high bilirubin value and assuming the entire diagnosis is settled.

What Causes IMHA in Dogs?

In many dogs, no associated cause is found.

When investigating a dog, veterinarians may consider:

• Tick-borne and other vector-borne infections

• Travel to regions where Babesia or other blood parasites occur

• Cancer

• Severe inflammatory disease

• Recent medication

• Toxin exposure

• Previous transfusion

• Envenomation

• Other immune-mediated disorders

Associations between IMHA and cancer, inflammation or medication vary greatly in strength. Finding another condition does not always prove that it caused the immune-mediated red blood cell destruction.

The work-up should therefore be tailored to the dog’s age, location, travel, examination findings and laboratory abnormalities rather than ordering every available test indiscriminately.

What Causes IMHA in Cats?

Feline IMHA is less common than canine IMHA, but it can be equally severe.

Important investigations in cats include:

• PCR testing for Mycoplasma haemofelis

• FeLV testing

• FIV testing

• Testing for Babesia in relevant regions

• Assessment for FIP when the clinical presentation warrants it

• Imaging for inflammation or cancer

• Review of medications and toxin exposure

The ACVIM consensus recommends M haemofelis PCR testing in all cats with IMHA. Evidence that M haemofelis can cause IMHA is strong, while evidence directly linking FeLV to immune-mediated destruction is much weaker than is sometimes claimed.

It is also incorrect to assume that most feline cases are caused by FeLV or hemotropic Mycoplasma.

In a retrospective study of 107 cats with IMHA, 72 were classified as having primary IMHA and 35 as having secondary IMHA. Infectious testing remains essential, but cats can develop non-associative immune-mediated disease without an identifiable infection.

Can Vaccination Trigger IMHA?

The relationship between vaccination and IMHA remains unsettled.

The 2019 ACVIM consensus found no high-level evidence proving that vaccination causes IMHA and concluded that current vaccination strategies were generally safe when individual risks and benefits were considered.

More recent research has added nuance. A 2026 multicentre study and systematic review found that dogs with IMHA were more likely than controls to have received a vaccine during the preceding 30 days in some analyses. However, the studies were heterogeneous and the authors specifically stated that the results did not establish a causal relationship. A separate 2026 evidence review concluded that evidence remained insufficient to determine whether vaccination increases IMHA risk and that current protocols appeared safe overall.

This means:

• A recent vaccination should be documented.

• Timing alone does not prove that the vaccine caused IMHA.

• Owners should not blame themselves for appropriately vaccinating their pet.

• Future vaccination decisions should be individualised after recovery.

• Vaccination is generally delayed during intensive immunosuppression because the immune response may be inadequate.

• A blanket lifelong ban on all vaccines is not automatically appropriate.

For a patient that has survived IMHA, the veterinarian should balance infection risk, previous vaccine history, antibody titres where useful, lifestyle and relapse concerns.

How Is IMHA Treated?

Treatment has several simultaneous goals:

1. Restore adequate oxygen delivery.

2. Slow immune-mediated red cell destruction.

3. Prevent blood clots.

4. Identify and treat any associated cause.

5. Monitor for complications and relapse.

Most patients with severe IMHA require hospitalisation.

Emergency Stabilisation

Initial care may include:

• Oxygen supplementation

• Intravenous access

• Careful fluid therapy

• Temperature support

• Continuous cardiovascular monitoring

• Repeated PCV or hematocrit measurements

• Blood pressure monitoring

• Assessment of urine output

• Blood typing and crossmatching

• Preparation for transfusion

Fluids must be used according to the individual patient. An anemic animal may need circulation support, but excessive fluid can dilute the remaining red blood cells or contribute to volume overload.

Blood Transfusions

A red blood cell transfusion does not stop IMHA. It provides functioning red blood cells while immunosuppressive medication begins controlling the disease.

The decision to transfuse should be based primarily on signs of inadequate oxygen delivery, including:

• Collapse

• Severe weakness

• Rapid or laboured breathing

• Persistent rapid heart rate

• Altered awareness

• Increasing lactate

• Progressive anemia

• Inability to maintain cardiovascular stability

There is no single PCV value at which every patient must be transfused. The speed of decline, the patient’s normal baseline, clinical signs and ability to monitor the patient all matter. The ACVIM consensus recommends packed red blood cells when clinical features indicate inadequate tissue oxygen delivery, with whole blood as an alternative when packed cells are unavailable.

Some animals require more than one transfusion because:

• Immune-mediated destruction is continuing

• The medication has not yet had enough time to work

• The initial transfusion was deliberately conservative

• There is concurrent bleeding

• Transfused cells are also being removed

The possibility of ongoing red blood cell destruction is not a reason to withhold a lifesaving transfusion. The transfusion is buying time.

Transfusions in cats

Cats must be blood typed before transfusion. Cats can have naturally occurring antibodies against incompatible blood types, and a mismatched transfusion can be rapidly fatal.

Crossmatching is also recommended where possible, including before a first transfusion, because incompatibilities outside the main AB blood group system can occur.

Immunosuppressive Treatment

Glucocorticoids

Prednisone or prednisolone is the standard first-line immunosuppressive treatment for canine IMHA.

Dexamethasone may be used temporarily when a patient cannot safely take oral medication.

These medications do not simply “kill immune cells”. They suppress several parts of the immune response, including antibody-driven removal of red blood cells by macrophages. They also reduce inflammatory activity while slower immune changes take effect.

Glucocorticoid adverse effects may include:

• Excessive thirst and urination

• Increased appetite

• Panting

• Muscle loss

• Gastrointestinal problems

• Behaviour changes

• Increased infection risk

• Elevated liver enzymes

• Blood clot risk

These effects can be significant, but the untreated disease is usually much more dangerous during the initial crisis.

Additional immunosuppressive medication

A second immunosuppressive medication may be considered when:

• Disease is immediately life-threatening

• The PCV or hematocrit continues to fall

• The patient remains transfusion-dependent

• The response to glucocorticoids is inadequate

• Severe steroid adverse effects develop

• A large dog would require a particularly high absolute glucocorticoid dose

• Relapse occurs during treatment

Options in dogs may include:

• Azathioprine

• Cyclosporine

• Mycophenolate mofetil

No second-line drug has been proven superior for every dog, and adding another medication from the beginning has not been proven necessary in every case. The choice depends on disease severity, expected onset of action, cost, monitoring requirements and adverse-effect risks.

Immunosuppressive treatment in cats

Prednisolone is commonly used as first-line treatment in cats.

Selected cats may receive another medication such as:

• Chlorambucil

• Cyclosporine

• Mycophenolate mofetil

The evidence supporting specific feline treatment combinations is much more limited than it is in dogs.

Azathioprine should not be used in cats because cats are highly susceptible to severe and potentially fatal bone marrow suppression from this drug.

Preventing Dangerous Blood Clots

Dogs with IMHA have a substantial risk of thrombosis.

Clots may form in:

• The pulmonary arteries

• The portal vein

• Other abdominal vessels

• The brain

• The limbs

• Other organs

Pulmonary thromboembolism can cause sudden rapid breathing, severe respiratory distress, collapse or death.

The ACVIM consensus recommends thromboprophylaxis for dogs with IMHA except those with severe thrombocytopenia, defined in the consensus as a platelet count below 30,000/µL. Active bleeding, kidney function, liver function and other individual factors must also be considered.

Treatment may involve:

• A heparin-based anticoagulant

• A direct oral anticoagulant

• An antiplatelet medication

• A combination selected for the individual patient

An anticoagulant-based strategy is generally preferred during the first two weeks when feasible because venous thrombosis is a major concern. If anticoagulation and its monitoring are not practical, antiplatelet treatment is preferred to giving no clot-prevention treatment.

When an antiplatelet drug is selected, the consensus favours clopidogrel over aspirin, although the evidence supporting one perfect protocol remains limited. Owners should never start aspirin, clopidogrel, heparin or another antithrombotic medication without veterinary instructions.

What Is Evans Syndrome?

Evans syndrome describes concurrent immune-mediated destruction of:

• Red blood cells, causing IMHA

• Platelets, causing immune-mediated thrombocytopenia

Affected patients may show signs of both anemia and bleeding, including:

• Pale gums

• Weakness

• Jaundice

• Bruising

• Pinpoint red spots on the skin or gums

• Nosebleeds

• Blood in the urine

• Black stool

• Prolonged bleeding

A low platelet count does not automatically remove the risk of thrombosis.

Dogs with Evans syndrome may have risks of both clotting and bleeding. The decision to use antithrombotic medication depends on the platelet count, active bleeding, coagulation findings and the patient’s overall condition.

The 2019 ACVIM consensus does not recommend a blanket avoidance of thromboprophylaxis in Evans syndrome. It recommends withholding it when severe thrombocytopenia is present below the stated threshold, with individual clinical judgement still required.

Treating an Associated Cause

When an associated condition is identified, it should be addressed alongside immunosuppressive treatment.

Examples include:

• Antimicrobial treatment for confirmed or strongly suspected infection

• Removal of a zinc foreign body

• Discontinuation of a suspected medication under veterinary guidance

• Treatment of inflammatory disease

• Management of cancer

• Treatment of concurrent pancreatitis or organ dysfunction

• Appropriate parasite control

Finding an associated condition may alter the prognosis, treatment duration and need for long-term immunosuppression.

How Long Does IMHA Treatment Continue?

Treatment usually continues for months rather than days.

For dogs, the ACVIM consensus describes a typical prednisone or prednisolone treatment period of approximately three to six months, with total immunosuppressive treatment often lasting four to eight months. Some dogs require longer treatment, and a small number need lifelong medication.

Dose reduction should only begin after the patient has shown a sustained response.

The consensus recommends considering the first glucocorticoid reduction once:

• PCV or hematocrit has remained stable above 30% for approximately two weeks

• Bilirubin is improving

• Agglutination and spherocytosis are improving

• The reticulocyte response is appropriate

• Clinical signs are improving

PCV or hematocrit should be checked before dose reductions and generally every one to three weeks during active treatment. The exact tapering schedule must be directed by the treating veterinarian.

Steroid medication must never be stopped suddenly.

Abrupt withdrawal can cause relapse and potentially dangerous adrenal insufficiency.

What Side Effects Should Be Monitored?

Immunosuppressed patients may develop:

• Increased thirst and urination

• Severe hunger

• Panting

• Muscle weakness

• Urinary infection

• Skin infection

• Gastrointestinal ulceration

• Vomiting or diarrhoea

• Liver enzyme elevation

• Bone marrow suppression

• Kidney or liver complications

• Opportunistic infection

• Drug-specific adverse effects

Follow-up may include:

• Complete blood count

• PCV or hematocrit

• Reticulocyte count

• Bilirubin

• Serum biochemistry

• Urinalysis

• Urine culture

• Blood pressure

• Drug concentration testing for selected medications

• Repeat imaging when an associated disease is being monitored

A normal PCV does not mean medication can immediately be stopped. The immune process may still be active even after the red blood cell count has recovered.

What Is the Prognosis for Dogs With IMHA?

There is no honest single survival percentage that applies to every dog.

Reported outcomes vary because of differences in:

• Disease severity

• Diagnostic criteria

• Referral populations

• Euthanasia decisions

• Transfusion availability

• Associated disease

• Treatment protocols

• Follow-up duration

A 2024 study of 104 dogs reported mortality of 16% by one month and 31% by three months among dogs with non-associative IMHA. For dogs surviving beyond the first three months, median survival was 2,664 days. The documented relapse rate was 7%. Thrombocytopenia and hyperbilirubinemia were independent negative prognostic indicators.

This illustrates the pattern seen clinically:

The acute phase carries the greatest danger. Long-term outcome can be good when the patient survives the first several weeks and enters stable remission.

Another 2024 study reported relapse rates of approximately 11% by 12 months and 18% by 24 months, showing that relapse estimates also vary between populations.

Findings that may worsen prognosis

More concerning findings include:

• Very high bilirubin

• Severe thrombocytopenia

• Persistent autoagglutination

• Continued rapid decline in PCV

• Repeated transfusion dependence

• Failure to respond to immunosuppression

• Confirmed thromboembolism

• Severe kidney or liver dysfunction

• Persistent high lactate or poor oxygen delivery

• Serious associated disease

• Neurological or respiratory complications

No individual value guarantees a poor outcome. Trends over the first days are usually more informative than one number at admission.

What Is the Prognosis for Cats With IMHA?

Feline prognosis depends strongly on whether the disease is primary or associated with another serious condition.

In a retrospective study of 107 cats:

• Median survival for primary IMHA was 516 days.

• Median survival for secondary IMHA was 14 days.

• Approximately 59% of primary cases with adequate follow-up were alive at six months.

• Approximately 26% of secondary cases were alive at six months.

Higher bilirubin and older age were associated with a worse outcome in primary feline IMHA.

These figures come from a retrospective referral population and cannot predict an individual cat’s outcome. A cat with a treatable infection may respond differently from a cat with advanced cancer, FIP or severe bone marrow disease.

Is IMHA Painful?

Anemia itself may not cause sharp pain, but affected animals can feel profoundly unwell.

They may experience:

• Air hunger

• Weakness

• Dizziness

• Nausea

• Headache-like discomfort

• Rapid heart rate

• Abdominal discomfort

• Muscle fatigue

• Anxiety caused by breathing difficulty

Blood clots, tissue hypoxia and associated inflammatory diseases can also be painful.

A very quiet patient should not be assumed to be comfortable. Severe anemia can leave an animal too weak to show normal signs of distress.

When Is IMHA an Emergency?

Suspected IMHA should be treated as an emergency whenever there are signs of anemia or hemolysis.

Go to an emergency veterinary hospital immediately for:

• White or markedly pale gums

• Yellow gums or eyes with weakness

• Collapse

• Inability to stand

• Rapid or laboured breathing

• Open-mouth breathing

• Severe lethargy

• Altered awareness

• Dark red or brown urine

• A rapidly enlarging abdomen

• Significant bruising or bleeding

• Black, tar-like stool

• Sudden neurological abnormalities

• A known IMHA patient becoming pale or weak again

Do not wait until the next morning to see whether a collapsed or profoundly weak animal improves.

What Should You Do Right Now?

If IMHA is suspected

1. Call the nearest veterinary hospital and explain that your pet may be severely anemic.

2. Keep your pet calm and restrict all physical activity.

3. Carry your pet when practical rather than making them walk.

4. Keep them comfortably warm without overheating.

5. Bring a list of every medication and supplement.

6. Bring recent blood results if available.

7. Tell the veterinarian about recent travel, ticks, vaccines, toxins and transfusions.

8. Be prepared for blood typing, crossmatching, hospitalisation and possible transfusion.

Do not give aspirin, iron, steroids, antibiotics or human medication unless a veterinarian has specifically instructed you to do so.

Iron will not correct rapid immune-mediated red cell destruction unless genuine iron deficiency is also present.

If your pet is recovering at home

Monitor:

• Gum colour

• Resting breathing

• Energy

• Appetite

• Urine colour

• Vomiting or diarrhoea

• Bruising or bleeding

• Medication administration

• Water intake and urination

• Body weight

• Any return of weakness

Give every medication exactly as prescribed and attend every scheduled blood test.

Contact the treating veterinarian immediately if symptoms recur or medication cannot be administered.

Common IMHA Mistakes to Avoid

Waiting for the gums to turn completely white

Significant anemia may already be present when the gums are only mildly pale.

Assuming one positive Coombs test confirms the diagnosis

The diagnosis requires evidence of anemia, immune-mediated destruction and hemolysis.

Refusing a necessary transfusion because the immune system may destroy the blood

Transfused red blood cells can restore oxygen delivery while treatment begins working. Without them, the patient may not survive long enough to respond.

Stopping steroids as soon as the PCV becomes normal

The red cell count may recover before the immune disease is fully controlled.

Reducing medication without a blood test

A patient may relapse before obvious symptoms return.

Giving aspirin or another blood thinner at home

The correct drug depends on platelet count, bleeding risk, species and concurrent disease. Incorrect treatment can cause severe bleeding.

Assuming Evans syndrome eliminates clot risk

Thrombocytopenia and thrombosis can coexist.

Assuming a recent vaccine definitely caused the disease

A temporal relationship does not prove causation. Future vaccination decisions should be individualised rather than driven by guilt or fear.

Ignoring reduced appetite or vomiting during treatment

These signs may indicate medication toxicity, gastrointestinal ulceration, infection, pancreatitis or another serious complication.

Can IMHA Be Prevented?

Non-associative IMHA cannot currently be reliably prevented.

Risk reduction may include:

• Consistent tick and flea prevention appropriate for the region

• Testing after relevant travel or tick exposure

• Preventing access to zinc-containing objects

• Keeping human medications away from pets

• Avoiding onions, garlic and other known oxidants

• Using medications only as directed

• Blood typing and compatibility testing before transfusion

• Investigating unexplained anemia promptly

• Individualising vaccination decisions after a previous IMHA episode

The most effective protective measure is early recognition.

A pet with pale gums, unexplained weakness or rapid breathing should be examined before collapse occurs.

Frequently Asked Questions

Can a dog survive IMHA?

Yes. IMHA has a significant acute mortality risk, but many dogs that survive the first weeks and enter remission can live for years. Outcome depends on disease severity, blood clot complications, response to treatment and associated disease.

Is IMHA contagious?

Primary or non-associative IMHA is not contagious. Some infections associated with hemolytic anemia can be transmitted by ticks, fleas, blood exposure or other vectors, but the immune-mediated disease itself does not spread directly between pets.

Can IMHA come back?

Yes. Relapse may occur during medication tapering or after treatment has finished. Pale gums, weakness, jaundice, dark urine or rapid breathing in a previously affected animal require urgent blood testing.

Can cats develop IMHA?

Yes. IMHA is less common in cats but can cause profound and life-threatening anemia. Cats require species-specific diagnostic interpretation, infectious disease testing and careful blood compatibility testing before transfusion.

Does vaccination cause IMHA?

Current evidence does not prove that vaccines cause IMHA. Recent studies have found a possible temporal association in some dogs, but they cannot establish causation. Vaccination decisions after IMHA should be individualised with the treating veterinarian.

Final Takeaway

Immune-mediated hemolytic anemia is a true veterinary emergency.

The immune system destroys red blood cells, reducing oxygen delivery and creating a substantial risk of blood clots, particularly in dogs. Pale gums, yellow discolouration, rapid breathing, profound weakness, dark urine or collapse require immediate care.

Diagnosis should not rely on one Coombs test or one blood smear finding. The strongest diagnosis combines evidence of anemia, immune-mediated red cell destruction and active hemolysis while investigating infectious, toxic, inflammatory and neoplastic alternatives.

Treatment may require transfusions, intensive immunosuppression, clot prevention and several months of monitoring. The first days and weeks are the highest-risk period, but patients that enter stable remission can have a much better long-term outlook than the initial crisis may suggest.

---

If you are dealing with a possible IMHA diagnosis, an unexpected blood result or signs that may indicate relapse, ASK A VET™ can help you organise the information and understand which questions need to be discussed with your treating veterinarian urgently.